Patients with previous allo-HSCT according to time from HSCT to relapse. Event-free survival (A), overall survival (B) with estimates for 24 months after CAR T-cell infusion, relapse-free survival (C), CIR (D), NRM (E), and duration of B-cell aplasia (F) with estimates for 24 months after response.